A bibliometric review examines tirzepatide's effects on liver disease, suggesting its potential role in treatment.
Tirzepatide combines potent metabolic effects with significant hepatic improvements, positioning it as a promising therapy for MASLD/MASH. Although long-term and phase III data are still needed, current evidence supports tirzepatide as a key component of modern metabolic liver disease management.
No takes yet. Share an insight, caveat, or question.
Pantea et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: